The GBA Multimodal Study in Parkinson's Disease

Launched by PACIFIC PARKINSON'S RESEARCH CENTRE · Sep 20, 2019

Keywords

ClinConnect Summary

The GBA Multimodal Study in Parkinson's Disease is a clinical trial that aims to understand how mutations in the GBA gene are connected to Parkinson's disease. Researchers will use advanced imaging technology called PET scans to look at how certain proteins behave in the brains of people with these gene mutations, both with and without Parkinson's. They are also interested in examining typing patterns as a way to identify early signs of motor problems in patients.

If you're between the ages of 18 and 80 and have a specific type of GBA gene mutation, you might be eligible to participate. However, this study cannot include individuals with other neurological disorders, certain medical implants, or severe claustrophobia. Participants can expect to undergo brain scans and assessments to help researchers learn more about the relationship between these gene mutations and Parkinson's disease. This study is currently recruiting participants and aims to uncover important insights that could improve understanding and treatment of the disease.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;
• • age 18 to 80 years.
• Exclusion Criteria:
• • co-occurrence of other neurological disorders;
• • implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);
• • severe claustrophobia;
• • intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);
• • ongoing treatment with cholinergic drugs